These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18391035)

  • 1. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate.
    Yang G; Wang J; Cheng Y; Dutschman GE; Tanaka H; Baba M; Cheng YC
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2035-42. PubMed ID: 18391035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly selective action of triphosphate metabolite of 4'-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT.
    Yang G; Dutschman GE; Wang CJ; Tanaka H; Baba M; Anderson KS; Cheng YC
    Antiviral Res; 2007 Mar; 73(3):185-91. PubMed ID: 17109975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
    Yang G; Paintsil E; Dutschman GE; Grill SP; Wang CJ; Wang J; Tanaka H; Hamasaki T; Baba M; Cheng YC
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4640-6. PubMed ID: 19704131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of HIV-1 reverse transcriptase/d4TTP complex: Novel DNA cross-linking site and pH-dependent conformational changes.
    Martinez SE; Bauman JD; Das K; Arnold E
    Protein Sci; 2019 Mar; 28(3):587-597. PubMed ID: 30499174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.
    Sohl CD; Kasiviswanathan R; Kim J; Pradere U; Schinazi RF; Copeland WC; Mitsuya H; Baba M; Anderson KS
    Mol Pharmacol; 2012 Jul; 82(1):125-33. PubMed ID: 22513406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.
    Ray AS; Yang Z; Shi J; Hobbs A; Schinazi RF; Chu CK; Anderson KS
    Biochemistry; 2002 Apr; 41(16):5150-62. PubMed ID: 11955063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
    Nitanda T; Wang X; Kumamoto H; Haraguchi K; Tanaka H; Cheng YC; Baba M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3355-60. PubMed ID: 16048947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTP.
    Vaccaro JA; Parnell KM; Terezakis SA; Anderson KS
    Antimicrob Agents Chemother; 2000 Jan; 44(1):217-21. PubMed ID: 10602755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
    Choi Y; George C; Comin MJ; Barchi JJ; Kim HS; Jacobson KA; Balzarini J; Mitsuya H; Boyer PL; Hughes SH; Marquez VE
    J Med Chem; 2003 Jul; 46(15):3292-9. PubMed ID: 12852759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, and in vitro enzymatic and antiviral evaluation of d4T polyphosphate derivatives as chain terminators.
    Yang S; Pannecouque C; Herdewijn P
    Chem Biodivers; 2012 Oct; 9(10):2186-94. PubMed ID: 23081918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
    Paintsil E; Dutschman GE; Hu R; Grill SP; Lam W; Baba M; Tanaka H; Cheng YC
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3870-9. PubMed ID: 17724147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases.
    Cherrington JM; Fuller MD; Mulato AS; Allen SJ; Kunder SC; Ussery MA; Lesnikowski Z; Schinazi RF; Sommadossi JP; Chen MS
    Antimicrob Agents Chemother; 1996 May; 40(5):1270-3. PubMed ID: 8723481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
    Smith RA; Raugi DN; Wu VH; Leong SS; Parker KM; Oakes MK; Sow PS; Ba S; Seydi M; Gottlieb GS;
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7437-46. PubMed ID: 26392486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.
    Lennerstrand J; Stammers DK; Larder BA
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2144-6. PubMed ID: 11408240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodrugs of γ-Alkyl-Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase.
    Zhao C; Weber S; Schols D; Balzarini J; Meier C
    Angew Chem Int Ed Engl; 2020 Dec; 59(49):22063-22071. PubMed ID: 32379948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance.
    Bertoletti N; Chan AH; Schinazi RF; Anderson KS
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33096918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance.
    Selmi B; Boretto J; Navarro JM; Sire J; Longhi S; Guerreiro C; Mulard L; Sarfati S; Canard B
    J Biol Chem; 2001 Apr; 276(17):13965-74. PubMed ID: 11134027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for activation of alpha-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptase.
    Meyer P; Schneider B; Sarfati S; Deville-Bonne D; Guerreiro C; Boretto J; Janin J; Véron M; Canard B
    EMBO J; 2000 Jul; 19(14):3520-9. PubMed ID: 10899107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.